CAMBRIDGE, Mass. , Sept. 30, 2024 /PRNewswire/ -- GentiBio, a leading cell and gene therapy company specializing in engineered regulatory T cells (Tregs), announced today the appointment of Mark Bach , M.
D., Ph.D.
as Chief Medical Officer. Dr. Bach brings over 30 years of experience in clinical research and development and has helped launch numerous innovative therapeutics into global markets.
In this role, Dr. Bach will oversee GentiBio's clinical development programs and will lead clinical strategy for its engineered Treg therapeutics for the treatment of autoimmune and inflammatory conditions. "Our lead asset GNTI-122 will enter the clinic in 2025 in Type 1 Diabetes, and Mark's leadership will be crucial as we advance to a clinical-stage company," said Andy Walker , Ph.
D., President and Chief Operating Officer of GentiBio. "His broad experience in taking biopharma companies through key stages of growth, particularly his ability to build and lead global clinical teams, complements our strategic vision and makes him an ideal addition to our leadership team.
We are excited to welcome him on board as we enter this next phase of development." Dr. Bach joins GentiBio from Structure Therapeutics where he served as Chief Medical Officer, driving the company's clinical strategy and overseeing product development.
Prior to that, he held senior leadership roles at several biopharmaceutical companies, including as Senior Vice President, Endocrine Medical Sciences at Ascendis Pharma, a.
